Piper Sandler and Bernstein Initiate Overweight Coverage on Roivant Sciences

Investment firms Piper Sandler and Bernstein have initiated coverage on Roivant Sciences Ltd with bullish ratings, pointing to significant upside potential in the biopharmaceutical sector. Piper Sandler launched its research on 16 April, assigning an Overweight rating and setting a price target of $40. The firm noted that the stock has already gained more than 190 per cent over the past year, a move supported by positive data and execution across the development of brepocitinib.

Bernstein initiated its own coverage earlier on 20 March, issuing an Outperform rating with a price target of $35. The research firm highlighted potential value from upcoming clinical readouts in pulmonary hypertension associated with interstitial lung disease and non-infectious uveitis. Both analysts agree that the primary driver for their positive outlook is the progress of brepocitinib in treating conditions such as dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.

Piper Sandler expects the company to achieve possible approval for dermatomyositis in the third quarter of 2026. The firm also forecasts Phase 3 CLARITY data for non-infectious uveitis in the second half of 2026, alongside the start of a Phase 3 study for cutaneous sarcoidosis by the end of 2026. Additionally, Piper Sandler pointed to the potential for expansion into lichen planopilaris, reinforcing the view that brepocitinib possesses multi-blockbuster opportunities.

Roivant Sciences operates using a distinctive model of creating subsidiaries, known as Vants, to develop and commercialise medicines. This approach allows the American biopharmaceutical company to focus on improving drug development and commercialisation through innovative technology. The firm's structure is designed to manage a variety of medicines and technologies efficiently, which analysts believe underpins the company's growth strategy.

Despite the optimistic ratings, Bernstein identified key risks that investors should monitor. The firm warned that negative results for brepocitinib in the Vygart Phase 3 trial for dermatomyositis could be a concern, particularly if the data appears better than expected. Furthermore, Bernstein highlighted the possibility of a softer-than-expected commercial launch as a factor that could impact the stock's performance, noting that these risks are already appropriately discounted in the valuation.

The coverage comes as market attention shifts toward healthcare equities, though broader market activity continues elsewhere. For instance, Bank of America recently raised its price target for Microsoft to $500 on 29 April, despite concerns regarding capital expenditures. While such movements occur in parallel, the specific focus on Roivant Sciences remains anchored in the clinical progress and strategic positioning of its lead asset.